Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP)

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a

Related Keywords

Australia ,Brisbane ,Queensland ,Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Australian ,Kathryn Morris ,Davidl Hoey ,Amy Miller ,University Of Queensland ,Development Authority ,International Convention ,Yates Network ,Australian Government Innovation Investment Fund ,United States Biomedical Advanced Research ,Oneventures Innovation Fund ,Vaxxas Chief Executive Officer David ,Science Advances ,Brandon Capital Partners ,Brandon Biocatalyst ,Healthcare Ventures ,Australian Government ,Innovation Investment Fund ,Press Release , ,